Regulation of Hematopoiesis by Ribosomal Protein Paralogs
核糖体蛋白旁系同源物对造血的调节
基本信息
- 批准号:8816656
- 负责人:
- 金额:$ 21.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-01-01 至 2019-12-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAddressAffectAmino Acid SequenceAnemiaAnimal ModelAutomobile DrivingBMP4BindingBiogenesisCD34 geneChimera organismCollectionDataDefectDependenceDevelopmentDiseaseDistalEctopic ExpressionEquilibriumGene SilencingGenesGrowthHematopoiesisHematopoietic stem cellsHumanLinkMessenger RNAMolecularMusPathologyPathway interactionsPhysiologicalPlayPositioning AttributeProcessProductionProtein BindingProteinsRNARNA BindingRNA Recognition MotifRegulationRibosomal ProteinsRibosomesRoleSequence HomologySignal TransductionSpecificityStagingStressStructural ProteinStructureSyndromeT-Cell DevelopmentT-LymphocyteTrans-ActivatorsTranslational RepressionTranslationsYeastsZebrafishbasebiological adaptation to stressclinically relevantdisease-causing mutationfetalhuman diseaseinsightloss of functionmouse modelnovelparalogous geneprogenitorpublic health relevanceskeletalthymocyte
项目摘要
DESCRIPTION (provided by applicant): Ribosomopathies are a collection of diseases caused by mutations in the structural proteins of the ribosome or in proteins that facilitate ribosome biogenesis. It is widely held that the developmental abnormalities that characterize ribosomopathies result from a generalized defect in ribosome biogenesis or function. In contrast to this view, we postulate that ribosomal proteins (RP) have the capacity to bind cellular RNAs outside the context of the ribosome, and that some human diseases are in fact caused by disruption of such distinct, "extra-ribosomal" functions. In support of this hypothesis, we have identified a paralogous pair of RNA-binding RP, Rpl22 and its paralog Rpl22-Like1 (Like1), that are dispensable for both the biogenesis and function of ribosomes, yet perform critical regulatory roles in hematopoiesis. Furthermore, despite their high degree of homology (>70% identical in amino acid sequence), we demonstrate that Rpl22 and Like1 perform distinct functions, i.e., a p53-dependent role in development of �T lymphocytes and a Smad1-dependent role in driving hematopoietic stem cell (HSC) emergence, respectively. Importantly, not only do Rpl22 and Like1 perform distinct functions, but those functions are also mutually antagonistic. Indeed, the block in HSC emergence caused by knockdown of Like1 is rescued by eliminating Rpl22. The fact that the RNA binding helices of Rpl22 and Like1 are identical suggests that these proteins bind largely overlapping sets of RNA targets but have different effects on the activities of those targets. Thus, we now seek to understand how these highly homologous RP perform antagonistic functions that are critical at distinct stages of hematopoiesis. We will do so according to three aims: 1) To determine how systemic loss of Rpl22 causes a selective arrest of developing T cells. 2) To elucidate the basis for the antagonistic functions of Rpl22 and Like1. 3) To understand how the antagonistic balance of Rpl22 and Like1 controls HSC emergence by regulating Smad1.
描述(由申请人提供):核糖体病是由核糖体结构蛋白或促进核糖体生物合成的蛋白突变引起的疾病的集合。人们普遍认为,核糖体病的发育异常是由于核糖体生物发生或功能的普遍缺陷造成的。与此观点相反,我们假设核糖体蛋白(RP)具有结合核糖体外的细胞RNA的能力,并且一些人类疾病实际上是由这种独特的“核糖体外”功能的破坏引起的。为了支持这一假设,我们已经鉴定了一对旁系同源的RNA结合RP,Rp 122及其旁系同源物Rp 122-Like 1(Like 1),它们对于核糖体的生物发生和功能都是同源的,但在造血中发挥关键的调节作用。此外,尽管它们具有高度同源性(氨基酸序列中>70%相同),我们证明Rp 122和Like 1执行不同的功能,即,分别是p53依赖的T淋巴细胞发育作用和Smad 1依赖的造血干细胞(HSC)出现作用。重要的是,Rp 122和Like 1不仅执行不同的功能,而且这些功能也是相互拮抗的。事实上,通过消除Rpl 22来挽救由Like 1的敲低引起的HSC出现的阻断。Rp 122和Like 1的RNA结合螺旋是相同的这一事实表明,这些蛋白质结合很大程度上重叠的RNA靶点组,但对这些靶点的活性具有不同的影响。因此,我们现在试图了解这些高度同源的RP如何执行拮抗功能,在造血的不同阶段是至关重要的。我们将根据三个目的这样做:1)确定Rp 122的全身性损失如何引起发育中的T细胞的选择性停滞。2)阐明Rp 122和Like 1拮抗功能的基础。3)为了了解Rp 122和Like 1的拮抗平衡如何通过调节Smad 1来控制HSC的出现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID L. WIEST其他文献
DAVID L. WIEST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID L. WIEST', 18)}}的其他基金
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10024573 - 财政年份:2020
- 资助金额:
$ 21.97万 - 项目类别:
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10462634 - 财政年份:2020
- 资助金额:
$ 21.97万 - 项目类别:
ThymUS 2020 International Conference on Lymphopoiesis
ThymUS 2020 国际淋巴细胞生成会议
- 批准号:
9913243 - 财政年份:2020
- 资助金额:
$ 21.97万 - 项目类别:
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10256631 - 财政年份:2020
- 资助金额:
$ 21.97万 - 项目类别:
The ThymUS 2016 International Conference on Lymphopoiesis
ThymUS 2016 国际淋巴细胞生成会议
- 批准号:
8986580 - 财政年份:2016
- 资助金额:
$ 21.97万 - 项目类别:
Molecular Basis for gamma/delta T Lineage Specification
gamma/delta T 谱系规范的分子基础
- 批准号:
8608275 - 财政年份:2014
- 资助金额:
$ 21.97万 - 项目类别:
Regulation of Hematopoiesis By Ribosomal Protein Paralogs
核糖体蛋白旁系同源物对造血的调节
- 批准号:
8880580 - 财政年份:2014
- 资助金额:
$ 21.97万 - 项目类别:
Regulation of hematopoiesis by ribosomal protein paralogs
核糖体蛋白旁系同源物对造血的调节
- 批准号:
10548846 - 财政年份:2014
- 资助金额:
$ 21.97万 - 项目类别:
Influence of ligand on specification of gamma/delta fate and function
配体对 γ/δ 命运和功能规范的影响
- 批准号:
8608276 - 财政年份:2014
- 资助金额:
$ 21.97万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 21.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 21.97万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 21.97万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 21.97万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 21.97万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 21.97万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 21.97万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 21.97万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 21.97万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 21.97万 - 项目类别: